3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
CNS
1
Conditions
Carcinoma, Medullary
5
Thyroid Neoplasms
4
Thyroid Cancer, Papillary
2
Familial medullary thyroid carcinoma
2
Adenocarcinoma, Follicular
2
Thyroid cancer, medullary
1
Thyroid Diseases
1
Thyroid Carcinoma, Anaplastic
1
Squamous Cell Carcinoma of Head and Neck
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms
1
Pheochromocytoma
1
Paraganglioma
1
Neuroendocrine Tumors
1
Multiple Endocrine Neoplasia Type 2b
1
Multiple Endocrine Neoplasia Type 2a
1
Multiple Endocrine Neoplasia
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Esthesioneuroblastoma, Olfactory
1
Differentiated Thyroid Cancer
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms, Male
1
Breast Neoplasms
1
Interventions
3-Iodobenzylguanidine
14
Temozolomide
6
lutetium Lu 177 dotatate
5
gallium Ga 68 dotatate
4
anlotinib
4
Specimen Handling
4
Everolimus
4
Radiotherapy
3
Phenoxybenzamine
3
Magnetic Resonance Spectroscopy
3
Doxorubicin
3
6-fluorodopamine
3
3-fluorobenzylguanidine
3
pegfilgrastim
2
olaparib
2
fluorodopa F 18
2
cabozantinib
2
belzutifan
2
Nivolumab
2
Ifosfamide
2
Granulocyte Colony-Stimulating Factor
2
Fluorodeoxyglucose F18
2
Filgrastim
2
Doxazosin
2
Dexmedetomidine
2
Capecitabine
2
Biopsy
2
Axitinib
2
Adrenalectomy
2
177Lu-octreotide, DOTA(0)-Tyr(3)-
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pheochromocytoma
×
vandetanib
×
Endocrine
×
Clear all
NCT01941849
2015-12-21
VIBRaNT
University College, London
Phase 1
Withdrawn